Article info

Extended report
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

Authors

  1. Correspondence to Dr Mark C Genovese, Division of Immunology and Rheumatology, 1000 Welch Road, Palo Alto, CA 94304, USA; genovese{at}stanford.edu
View Full Text

Citation

Genovese MC, Fleischmann R, Furst D, et al
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

Publication history

  • Received October 15, 2013
  • Revised January 27, 2014
  • Accepted February 16, 2014
  • First published March 18, 2014.
Online issue publication 
July 31, 2014

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.